» Articles » PMID: 33737933

Inhibition of Dendritic Cell Activation and Modulation of T Cell Polarization by the Platelet Secretome

Overview
Journal Front Immunol
Date 2021 Mar 19
PMID 33737933
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Platelet transfusions are a frequently administered therapy for especially hemato-oncological patients with thrombocytopenia. Next to their primary function in hemostasis, currently there is increased attention for the capacity of platelets to affect the function of various cells of the immune system. Here, we investigate the capacity of platelets to immuno-modulate monocyte-derived dendritic cells (moDC) as well as primary dendritic cells and effects on subsequent T cell responses. Platelets significantly inhibited pro-inflammatory (IL-12, IL-6, TNFα) and increased anti-inflammatory (IL-10) cytokine production of moDCs primed with toll-like receptor (TLR)-dependent and TLR-independent stimuli. Transwell assays and ultracentrifugation revealed that a soluble factor secreted by platelets, but not microvesicles, inhibited DC activation. Interestingly, platelet-derived soluble mediators also inhibited cytokine production by human stimulated myeloid CD1c+ conventional DC2. Moreover, platelets and platelet-derived soluble mediators inhibited T cell priming and T helper differentiation toward an IFN+ Th1 phenotype by moDCs. Overall, these results show that platelets are able to inhibit the pro-inflammatory properties of DCs, and may even induce an anti-inflammatory DC phenotype, with decreased T cell priming capacity by the DC. The results of this study provide more insight in the potential role of platelets in immune modulation, especially in the context of platelet transfusions.

Citing Articles

Conjoint analysis of methylation, transcriptomic, and proteomic profiles in pemphigus vulgaris.

Luo X, Ouyang J, Jiang F, Zhang Y, Wang Y, Wu Y Orphanet J Rare Dis. 2024; 19(1):437.

PMID: 39593117 PMC: 11590579. DOI: 10.1186/s13023-024-03458-6.


The dynamic role of platelets in cancer progression and their therapeutic implications.

Li S, Lu Z, Wu S, Chu T, Li B, Qi F Nat Rev Cancer. 2023; 24(1):72-87.

PMID: 38040850 DOI: 10.1038/s41568-023-00639-6.


[Recent research on platelet-leukocyte aggregates and their role in the pathogenesis of Kawasaki disease].

Gao L, Gong F Zhongguo Dang Dai Er Ke Za Zhi. 2023; 25(6):587-594.

PMID: 37382127 PMC: 10321433. DOI: 10.7499/j.issn.1008-8830.2302066.


Effects of the interactions between platelets with other cells in tumor growth and progression.

Li Y, Wang H, Zhao Z, Yang Y, Meng Z, Qin L Front Immunol. 2023; 14:1165989.

PMID: 37153586 PMC: 10158495. DOI: 10.3389/fimmu.2023.1165989.


Platelet, a key regulator of innate and adaptive immunity.

Yan C, Wu H, Fang X, He J, Zhu F Front Med (Lausanne). 2023; 10:1074878.

PMID: 36968817 PMC: 10038213. DOI: 10.3389/fmed.2023.1074878.


References
1.
Esebanmen G, Langridge W . The role of TGF-beta signaling in dendritic cell tolerance. Immunol Res. 2017; 65(5):987-994. DOI: 10.1007/s12026-017-8944-9. View

2.
Nishat S, Wuescher L, Worth R . Platelets Enhance Dendritic Cell Responses against Staphylococcus aureus through CD40-CD40L. Infect Immun. 2018; 86(9). PMC: 6105897. DOI: 10.1128/IAI.00186-18. View

3.
Estcourt L, Stanworth S, Doree C, Hopewell S, Murphy M, Tinmouth A . Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation. Cochrane Database Syst Rev. 2012; (5):CD004269. DOI: 10.1002/14651858.CD004269.pub3. View

4.
Calzetti F, Tamassia N, Micheletti A, Finotti G, Bianchetto-Aguilera F, Cassatella M . Human dendritic cell subset 4 (DC4) correlates to a subset of CD14CD16 monocytes. J Allergy Clin Immunol. 2018; 141(6):2276-2279.e3. DOI: 10.1016/j.jaci.2017.12.988. View

5.
Duerschmied D, Bode C, Ahrens I . Immune functions of platelets. Thromb Haemost. 2014; 112(4):678-91. DOI: 10.1160/TH14-02-0146. View